KalVista, Health Catalyst, Bio-Techne Lead After-Hours Gains On Earnings Updates

Several healthcare and biotech stocks posted notable after-hours gains on Monday, driven by recent earnings reports and updated guidance. Assertio Holdings (ASRT) climbed 8.30% after reporting a strong Q3 GAAP net income of $11.4 million and increased product sales, alongside narrowing its full-year 2025 guidance for sales and adjusted EBITDA. Health Catalyst (HCAT) advanced 13.24% despite a Q3 net loss, providing Q4 and full-year revenue and adjusted EBITDA projections, while KalVista Pharmaceuticals (KALV) also rose 11.29% following its Q3 earnings release.

Analysis

Several healthcare and biotech stocks experienced notable after-hours gains, primarily driven by recent earnings reports and updated financial guidance. This sector-specific uplift suggests investor focus on company-specific fundamentals and future outlooks, despite broader market conditions. The overall sentiment for these movements is moderately positive, indicating a favorable, albeit cautious, market reception.

Assertio Holdings (ASRT) demonstrated strong performance, gaining 8.30% after reporting a significant Q3 GAAP net income of $11.4 million, a reversal from a $2.9 million loss year-over-year, alongside robust net product sales growth to $49.5 million. The company further solidified investor confidence by narrowing its full-year 2025 guidance for net product sales to $110-$112 million and adjusted EBITDA to $14-$16 million. In contrast, Health Catalyst (HCAT) advanced 13.24% despite a Q3 revenue decline to $76.3 million and an increased net loss, likely buoyed by its Q4 2025 revenue projection of $73.5 million and adjusted EBITDA of $13.4 million.

KalVista Pharmaceuticals (KALV) rose 11.29% despite reporting an increased Q3 net loss of $49.5 million, with its $13.7 million in net product revenue potentially offering some offset. Bio-Techne (TECH) climbed 8.72% on flat adjusted EPS and a 1% revenue decline, suggesting market focus on other aspects or prior positive sentiment. Abeona Therapeutics (ABEO) also saw an 8.51% increase ahead of its Q3 results, indicating speculative interest or anticipation of positive news.

Key Decisions for Investors

• Investors should conduct thorough due diligence on companies like Health Catalyst (HCAT) and KalVista (KALV) where after-hours gains contradict reported losses or revenue declines, focusing on forward guidance and specific catalysts.
• For Assertio Holdings (ASRT), consider its strong Q3 performance and narrowed 2025 guidance as indicators of improving fundamentals, warranting further analysis into its competitive landscape and growth trajectory.
• Exercise caution with pre-earnings movers like Abeona Therapeutics (ABEO), as their gains are speculative and actual Q3 results on November 12 could introduce significant volatility.